Gastrointestinal Motility Assays

Gastrointestinal motility (GIM) assays are designed to understand the effect of drug candidates on GIM (contraction and dilation). Assessing the therapeutic ability and safety of candidate drugs by GIM assay can provide an important basis for drug development, optimize treatment options and reduce the risk of drug development. Creative Biolabs provides GIM assays based on various physiological or disease gastrointestinal (GI) models to help customers evaluate the therapeutic effect and safety of candidate drugs in terms of GIM.

Fig.1 Fluorescent time-course optical images of peristatic pumping through human gastric organoid.¹

GIM Assay for Drug Development in Gastrointestinal (GI) Diseases

The gastrointestinal tract (GIT) is an important organ in the human body for digestion and absorption of nutrients. However, GI diseases such as gastric ulcer, peptic ulcer, inflammatory bowel disease, and gastroesophageal reflux disease pose a significant burden to the global population. Therefore, it is urgent to develop more effective and safer drugs for treating GI diseases. GIM measurements are essential during drug development for GI disorders.

Evaluate the therapeutic effect of drugs in the GIT: the kinetic properties of candidate drugs in the GIT can be evaluated by GIM assay. These parameters play an important role in evaluating the absorption, distribution, and efficacy of drugs. Understanding how drugs behave in the GIT can help optimize drug efficacy.
Accelerated drug screening: through the determination of GIM, the therapeutic effect of different drugs in the GIT can be evaluated. According to the effect of drugs on GIM, candidate drugs can be further screened to improve the efficiency of drug development.
Optimizing the drug dosage form design: according to the movement and metabolism characteristics of a drug in the GIT, the design of the drug dosage form can be optimized, such as controlled release dosage form, sustained release dosage form, etc., to prolong the residence time of the drug in the GIT and improve the absorption effect of the drug.

GIM Assay for Drug Candidate Safety Assessment

Candidate drugs may have adverse reactions such as bloating, constipation, nausea, vomiting, abdominal pain, and ulcers in the subsequent treatment. The causes of these adverse reactions may involve a variety of factors.

Target action mechanism	Drug metabolism and excretion
The action mechanism of some drugs may affect neuromodulation, muscle contraction, and other aspects of the GIT. If the combination of drugs with GI-related targets interferes with normal physiological regulation, it may lead to abnormal GIM.	The metabolism and excretion process of drugs in the body may also affect GIM. Some drugs or their metabolites may interfere with nerve conduction or affect muscle contraction, thereby causing disturbance of GIM.
Tissue tolerance	Drug interactions
The GIT may have differential tolerance to certain drugs. Certain drug candidates may have irritating or toxic effects on GI tissues, leading to changes in GIM and the occurrence of adverse reactions.	Some drugs may interact with other drugs or substances in the GIT, resulting in changes in GIM. The interaction between drugs may enhance or weaken their impact on the GIT, thereby affecting the normal function of GIM.

GIM Assay Services at Creative Biolabs

By evaluating the therapeutic effect and safety of drug candidates through GIM assays based on 3D models or organoids, Creative Biolabs can more accurately evaluate the behavior and effects of drug candidates in the GIT and provide more reliable data support.

Experimental design

Constructing GI disease models

Drug processing

Kinetic Determination

Data Analysis and interpretation

If you are in doubt about the effect of drug candidates on GIM, please contact us for the most comprehensive GIM measurement service.

Reference